Cytek Investor Conference Presentation Deck
Cytek at a Glance (as of Q3-2023) (1)
Broad Customer Base
and Global Presence
Validated
Technology Platform
1,997
Cytek FSP Units
Placed
1,450+
Cytek FSP Peer-
reviewed Publications
CYTEK
TRANSCEND THE CONVENTIONAL
1,500+
Customers
70+
Countries
Trailing 12 months as of (9/30/2023)
Strong
Financial Profile
1. As of Q3'23
2. Acquired from Luminex in February 2023
3. Announced partnership with Bio-Rad for use of StarBright dye portfolio in February 2023
4. Acquired from Tonbo in November 2021
5. Preliminary and unaudited; estimate as of January 8, 2024
$183.1M
$9.3M
TTM Revenue/
A-EBITDA
$288M
Net
Cash/Equivalent
2023 Outlook
Revenue for the full year 2023 expected to be
near the high-end of the $188 - $192M guidance range (5)
Productive R&D
and BusDev Engine
Cytek Orion
Amnis &
Guava (2)
StarBright
Reagents (3)
CE-IVDD
Tonbo
Reagents (4)
Cell
Sorter
cFluor
Reagents
Northern
Lights
Cytek Aurora
Athena
2023
2023
2023
2022
2021
2021
2020
2018
2017
2016
4View entire presentation